Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Smoldering Multiple Myeloma × IPH-2101 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 2 Smoldering Multiple Myeloma 1

Interventions

daratumumab 2 siltuximab 1 sargramostim 1 elotuzumab 1 PVX-410 vaccine 1 Monatide (IMS 3015) 1 Lenalidomide 1 IPH-2101 1 Emulsions 1 BHQ880 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01222286 2014-05-09

KIRMONO

Innate Pharma

Phase 2 Completed

30 enrolled 10 charts

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡